Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.78 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052939 | 0.88 | TAAR1 (1.00) | TAAR1AOC3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11250748 | 0.80 | HRH1 (0.60) | TAAR1HRH3 | |
| Maleic Acid SCHEMBL28690962 | 0.79 | TAAR1 (0.50) | TAAR1AOC3SLC6A4SLC6A2 | |
| SCHEMBL11264682 | 0.79 | TAAR1 (0.58) | TAAR1HRH3 | |
| SCHEMBL9670821 | 0.79 | SIGMAR1 (0.63) | TAAR1SLC6A4SIGMAR1 | |
| SCHEMBL1822278 | 0.78 | TAAR1 (0.62) | TAAR1AOC3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL18940166 | 0.78 | TAAR1 (0.58) | TAAR1AOC3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL28237237 | 0.78 | TAAR1 (0.49) | TAAR1AOC3SLC6A4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL11258745 | 0.78 | TAAR1 (0.57) | TAAR1HRH3 | |
| SCHEMBL11269198 | 0.78 | TAAR1 (0.57) | TAAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003104216-A1 | UROTENSIN II RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | disclosed |